Nyheter

Navamedic ASA: Q4 2018 financial results

Oslo, 14 February 2019 – Navamedic ASA (OSE: NAVA) reported revenues of NOK 51.8 million in the fourth quarter of 2018, up 14.7% from the same period in 2017, and an EBITDA of NOK 1.6 million (-2.4). Navamedic has a new Board of Directors, a new CEO, a new anchor investor and sees a strong potential in the highly scalable market access platform, based on current products, the pipeline and arising M&A opportunities.

Navamedic acquires Novicus Pharma

Reference is made to the stock exchange announcement made by Navamedic ASA (the "Company" or "Navamedic") on 21 December 2018 concerning the process of a potential acquisition of Novicus Pharma AS ("Novicus Pharma" or "Novicus").

Extraordinary general meeting held

Navamedic ASA: Innkalling til ekstraordinær generalforsamling